# Bone Biologics Corp: Form 10-Q for the period ended Jun 30, 2023

- Company: [Bone Biologics Corp](/companies/bblg.md) (CIK 1419554)
- Form: 10-Q
- Filed: 2023-08-14
- Accepted by EDGAR: Aug 14, 2023, 15:17 ET
- Period: 2023-06-30
- Accession: 0001493152-23-028330
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1419554/000149315223028330/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1419554/000149315223028330/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2023-04-01 to 2023-06-30 | $2.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2023-01-01 to 2023-06-30 | $4.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-04-01 to 2023-06-30 | −$3.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2023-01-01 to 2023-06-30 | −$6.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2023-04-01 to 2023-06-30 | −$1.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2023-01-01 to 2023-06-30 | −$5.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-04-01 to 2023-06-30 | −$1.69 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2023-01-01 to 2023-06-30 | −$6.90 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-04-01 to 2023-06-30 | −$1.69 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2023-01-01 to 2023-06-30 | −$6.90 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-04-01 to 2023-06-30 | 1,047,022 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2023-01-01 to 2023-06-30 | 793,537 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2023-01-01 to 2023-06-30 | −$5.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2023-06-30 | $7.0m | us-gaap:Cash |
| Total assets | at 2023-06-30 | $7.6m | us-gaap:Assets |
| Current liabilities | at 2023-06-30 | $1.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-06-30 | $1.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-06-30 | $5.7m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1419554/000149315223028330/form10-q.htm

Filed Aug 14, 2023.
Source: SEC EDGAR, the filing index for accession 0001493152-23-028330. Last ingested by Listed: Nov 11, 2026, 03:46 ET. No prices; not investment advice.
